A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm
Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is still…
Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is still…
The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery…
The UK and India’s newly signed £4.8bn ($6.45bn) free trade agreement (FTA) is expected to give rise to new opportunities…
Life sciences venture capital (VC) company Omega Funds has closed its eighth fund, with capital commitments totalling $647m. As with…
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for EURneffy, an adrenaline (epinephrine) nasal spray for…
According to GlobalData analysis, currently marketed and pipeline cell therapy assets in oncology will generate sales of around $25bn by…
Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around…
With the US Food and Drug Administration (FDA) shifting its clinical trial regulations in recent years, working closely with regulators…
The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a…
US President Donald Trump’s One Big Beautiful Bill Act (H.R. 1) has narrowly passed after US Vice President JD Vance…